FDA Enforcement In Brief
This article was originally published in The Tan Sheet
Executive Summary
Perrigo facility undergoes reinspection
You may also be interested in...
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Perrigo stokes momentum behind already healthy sales growth with significant steps in separate areas: a green light for regulatory compliance at its main manufacturing plant, and the launch of its generic OTC versions of Sanofi-Aventis' Allegra.
Perrigo Absorbs Plant Remediation Sales Hit, But PBM Progresses In Q1
Continuing remediation at a facility that received an FDA warning letter took a bite out of first-quarter sales for Perrigo, but the private labeler sees continued upside in branded competitor recalls and infant formula growth in the rest of fiscal 2011.
Sandoz Prepares For European Natalizumab Launch As Approval Arrives
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.